Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT)

This investigation is for anyone who acquired securities in Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) prior to August 2, 2022.

The Law Offices of Howard G. Smith believes that the Company and certain of its executives violated federal law. Specifically, the Law Offices of Howard G. Smith believes that the Company misled investors regarding its financial condition. More specifically, the Law Offices of Howard G. Smith believes that the Company misled investors by telling investors that it had controls in place to prevent its drugs from containing impurities but then allowing impurities into its vonoprazan drug product.

On August 2, 2022, Phathom disclosed that it had “detected trace levels of a nitrosamine in vonoprazan drug product in [its] post-approval testing as [it] prepared for commercial launch.” As a result, the Company planned to seek approval for additional testing methods and controls “to address this impurity prior to releasing [its] first vonoprazan-based products to the market.” The Company also stated that this will result in a delay of planned product launches. On this news, the price of the Company’s stock dropped precipitously on unusually heavy trading volume.

The Law Offices of Howard G. Smith seeks to recover damages on behalf of class members. If you acquired securities in Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) prior to August 2, 2022 you may join the lawsuit by submitting your information online, or you may call the Law Offices of Howard G. Smith and speak to Mr. Smith directly to learn how he can protect your rights.